制定阮綜合醫療社團法人阮綜合醫院乳癌 (Breast Cancer) 治療共識
|
|
- Corey Wilcox
- 5 years ago
- Views:
Transcription
1 制定阮綜合醫療社團法人阮綜合醫院乳癌 (Breast Cancer) 治療共識 修訂 修訂 審閱 LCIS (Lobular Carcinoma in Situ) 修訂 修訂 Diagnosis Workup Risk Reduction Surveillance Biopsy was core needle biopsy (less than surgical biopsy) Perform surgical excision Ductal carcinoma in situ(dcis) or invasive cancer Manage per appropriate NCCN Guideline Lobular carcinoma in situ (LCIS) identified on breast biopsy.history and physical.diagnostic bilateral mammogram.pathology review.breast sonography Initial biopsy was surgical biopsy LCIS without other cancer. Counseling regarding risk reduction, see NCCN Breast Cancer Risk Reduction Guidelines Surveillance as per.nccn Breast Cancer Risk Reduction Guidelines.NCCN Breast Cancer Screening and Diagnosis Guidelines. LCIS-1
2 DCIS (Ductal Carcinoma in Situ) Diagnosis Workup Primary Treatment Lumpectomy d,e without lymph node Ductal Carcinoma in Situ (DCIS) Stage 0 Tis, N0, M0.History and physical exam.diagnostic bilateral mammogram.pathology review.determination of tumor estrogen receptor (ER) status.genetic counseling if patient is high risk surgery + whole breast rediation therapy (Category 1) g,h,i,j,k or Total mastectomy with or without sentinel node biopsy f,i ± reconstruction or See Postsurgical Treatment (DCIS 2) for hereditary breast cancer.breast sonography Lumpectomy d,e without lymph node surgery without radiation therapy (category 2B) h,j,k DCIS-1
3 DCIS (Ductal Carcinoma in Situ) DCIS Postsurgical Treatment Surveillance/Follow-up Risk reduction therapy for ipsilateral breast following breast conserving surgery: Consider Tamoxifen m for 5 years for:.patients treated with breast-conservation therapy( lumpectomy) and radiation therapy (category 1), n especially for those with ER-positive DCIS. The benefit of Tamoxifen for ER-nagative DCIS is uncertain.patients treated with excision alone n Risk reduction therapy for contralateral breast:.counseling regarding consideration of Tamoxifen for risk reduction (category 2B). m.interval history and physical exam every 6~12 mo for 5 years, then annually.mammogram every 12 mo (and 6~12 mo postradiation therapy if breast conserved category 2B ).If treated with Tamoxifen, monitor per NCCN Breast Cancer Risk Reduction Guidelines.Breast sonography every 3 mo for 1 year, then every 6 mo for 5 years. DCIS-2
4 DCIS (Ductal Carcinoma in Situ) DCIS-A
5 Invasive Breast Cancer Clinical Stage Locoregional Treatment Systemic Adjuvant Therapy Ductal, Lobular, Mixed, Metaplastic.Stage IA T1N0M0.Stage IB T0N1miM0 T0N1miM0.Stage IIA T0N1M0 T1N1M0 T2N0M0.Stage IIB T2N1M0 T3N0M0.Stage IIIA T0N2M0 T1N2M0 T2N2M0 T3N1M0 T3N2M0.MRM.Total mastectomy (TM) + ALND.TM + SLNB.+ RT (RT indicated: if 4 positiive axillary nodes or tumor > 5cm or margin positive or margin <1mm axillary node 1~3 positive is strongly consider).lumpectomy + ALND + RT.Lumpectomy + SLNB + RT (RT follow C/T when C/T indicated) Hormone receptor (-).T 0.5cm, pn0, no therapy.t 0.5cm, pn1mi, ±C/T.T0.6~1cm pn0 pn1mi, ±C/T.T>1cm N0, or any T node positive, +C/T Hormone receptor (+).T 0.5cm, pn0, ±HT (Hormone Therapy).T 0.5cm, pn1mi, +HT ±C/T.T0.6~1cm pn0 pn1mi, +HT ± C/T.T>1cm N0, or any T node positive, +HT ±C/T (HR+, Her0, N0, T>0.5cm pn0 可進行 RT-PCR assay, 健保不給付, 需病患同意自費 ) HER2(+), 除 T 0.5cm pn0 外需建議 + Trastuzumab( 健保只給付淋巴轉移 ) Tubular, Colloid.MRM.TM + ALND.TM + SLNB.+RT (RT indicated: if 4 positiive axillary nodes or tumor > 5cm or margin positive or margin <1mm axillary node 1~3 positive is strongly consider).lumpecomy + ALND + RT.Lumpecomy + SLNB + RT (RT follow C/T when C/T indicated) Hormone receptor (-).Repeat ER/PR status, if still negative, treat us usual breast histology Hormone receptor (+).Tumor size <1cm, N0, No therapy.tumor size 1~2.9cm, N0, ±HT.Tumor size 3cm, N0, or any T node IBC-1
6 Invasive Breast Cancer Clinical Stage Primary Treatment Locoregional Treatment Adjuvant Treatment Stage IIA, IIB, IIIA and fulfills criteria for breast conserving.neoadjuvant chemotherapy.ht (if ER positive).mrm.bcs + ALND.+ RT.+ HT (if ER positive).+ C/T LABC.Stage IIIA T0N2M0.Stage IIIB T1N2M0 T2N2M0 T3N1M0 T3N2M0 T4N0M0.Neoadjuvant chemotherapy Response.MRM + RT.BCS + ALND + RT No Response.+ C/T ±RT.+ C/T.+ HT (if hormone receptor positive).individualized Treatment T4N1M0 T4N2M0.Stage IIIC Any T N3M0.Stage IV Any T Any N M1 Hormone receptor (+).+ HT Hormone receptor (-), or HT refractory.+ C/T.+ Trastuzumab (if Her2 positive).+ RT.+ OP If no response.palliative Care IBC-2
7 Paget s Disease Clinical Presentation Workup Examination or imaging positive for breast lesion Clinical suspicion of Paget s disease a.clinical breast exam.diagnosis bilateral mammogram, ultrasound as necessary See PAGET-2 Examination and imaging negative for breast lesion PAGET-1
8 Paget s Disease Workup Treatment Breast and NAC biopsy negative Clinical follow-up Re-biopsy if not healing Examination or imaging positive for breast lesion Examination and Core biopsy of breast lesion and full thickness skin biopsy of involved nipple-areola complex (NAC) Full thickness skin Breast DCIS b and NAC Paget s Breast invasive cancer and NAC Paget s b,e Breast negative for cancer and positive NAC Paget s b NAC biopsy positive for Paget s b Mastectomy ± axillary staging c or Excision of breast tumor and excision NAC with whole breast radiation, consider boost to breast and NAC sites d Mastectomy+axillary staging (See BINV-D) or Excision of breast tumor and excision NAC+axillary staging (See BINV-D) with whole breast radiation, consider boost to breast and NAC sites Consider MRI and tissue sampling Mastectomy+axillary staging (See BINV-D) or Excision of NAC with whole breast radiation, consider boost to NAC sites d Appropriate systemic adjuvant therapy imaging negative for breast lesion biopsy of involved NAC NAC biopsy negative for Paget s Clinical follow-up Re-biopsy if not healing PAGET-2
9 Breast Cancer During Pregnancy Clinical Presentation Primary Treatment a Adjuvant Treatment a 1st trimester Discuss termination: Non-therapeutic Continuing pregnancy Mastectomy + axillary staging a,b,c Begin adjuvant chemotherapy in 2nd trimester a ±Adjuvant radiation therapy ±Adjuvant endocrine therapy Pregnant patient with confirmed breast cancer diagnosis (core biopsy preferred) No distant metastases on staging 2nd trimester/ Early 3rd trimester Mastectomy a or breast-conserving surgery + axillary staging a,b,c or Adjuvant chemotherapy a ± Adjuvant radiation therapy ± Adjuvant endocrine therapy Neoadjuvant chemotherapy a, mastectomy or breast-conserving surgery + axillary staging a,b,c post-partum ±Adjuvant radiation therapy ±Adjuvant endocrine therapy Late 3rd trimester Mastectomy a or breast-conserving surgery + axillary staging a,b,c Adjuvant chemotherapy a ± Adjuvant radiation therapy ± Adjuvant endocrine therapy PREG-1
10 Phyllodes Tumor Clinical Presentation Work Up Findings Treatment Fibroadenoma Observe Excisional biopsy b Phyllodes tumor includes benign, borderline and malignant Wide excision c without axillary staging Clinical suspicion of phyllodes tumor:.palpable mass.rapid growth.large size (>2cm).Imaging with ultrasound suggestive of fibroadenoma except for size and/or history growth.history and physical exam.ultrasound.mammogram for women 30y Invasive or in situ cancer Fibroadenoma or indeterminate See appropriate guidelines Excisional biopsy b See findings above Core needle biopsy a Phyllodes tumor Wide excixion c without axillary staging Invasive or in situ cancer See appropriate guidelines PHYLL-1
11 Phyllodes Tumor Recurrence Phyllodes Tumor Clinical Presentation Work Up Findings Treatment No metastatic disease Re-excision with wide margins without axillary staging Consider post-operative radiation d Locally recurrent breast mass following excision of phyllodes tumor.history and physical exam.ultrasound.mammogram.tissue sampling (histology preferred).consider chest imaging Metastatic disease Metastatic disease management following principles of soft tissue sarcoma PHYLL-2
12 Inflammatory Breast Cancer Clinical Presentation a Work Up Clinical pathologic diagnosis of IBC Staging T4d, N0-N3, M0.History and physical exam.cbc, Platelets.Liver function tests.pathology review b.determination of tumor ER/PR status and Her2 status c.bilateral diagnostic mammogram, ultrasound.breast MRI (optional).bone scan or fluoride PET/CT d.abdomen sonography.chest diagnostic CT.FDG PET/CT scan f (optional) Preoperative chemotherapy, g Anthracycline + Taxane (preferred) g if tumor Her2 positive, trastuzumab containing regimen but not concurrent with Anthracycline Response No response IBC-1
13 Inflammatory Breast Cancer Treatment Response Total mastectomy + level I/II axillary dissection + radiation therapy to chest wall and supraclavivular nodes (plus internal mammary nodes if involved, consider internal mammary nodes if not clinically involved) ± delayed breast reconstruction i Complete planned chemotherapy j regimen couse if not completed preoperatively plus endocrine treatment if estrogen receptor positive (sequential chemotherapy followed by endocrine therapy). Complete 1 year of trastuzumab if tumor Her2-positive Response See above pathway No response Consider additional systemic chemotherapy j and/or preoperative radiation No response Individualized treatment IBC-2
Adjuvant treatment Tamoxifen for 5 years ER or uncertain Risk reduction for contralateral breast cancer optional AI may also be considered
共識診斷 臨床檢查 主要治療 輔助治療 術後追蹤 DCIS TisN0M0 LCIS TisN0M0 ER/PR/Her-2 ER/PR/Her-2 1. Partial mastectomy SLNB whole breast radiation therapy 2. Total mastectomy SLNB reconstruction Risk reduction surgery Adjuvant
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationNCCN Clinical Practice Guidelines in Oncology. Breast Cancer V Continue.
Clinical in Oncology V.1.2010 Continue www.nccn.org Robert W. Carlson, MD/Chair Stanford Comprehensive Cancer Center D. Craig Allred, MD Siteman Cancer Center at Barnes-Jewish Hospital and Washington University
More informationJose A Torres, MD 1/12/2017
Jose A Torres, MD 1/12/2017 Background Globally leading cause of cancer related death in women ~249,000 Americans diagnosed with invasive breast cancer ~40,890 will die of their disease Breast cancer risk
More informationCancer Program Report 2014
Cancer Program Report 2014 Queen of the Valley Hospital St Joseph Health Queen of the Valley Hospital - 2014 Site Table Site Total Class Sex Group Cases Analytic NonAn M F 0 I II ALL SITES 661 494 167
More informationCompleting the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017
Completing the Puzzle AJCC TNM Staging Breast Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017 OBJECTIVES Understanding of Breast TNM staging Identify clinical
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationClinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair
Clinical Trials of Proton Therapy for Breast Cancer Andrew L. Chang, MD 張維安 Study Chair AndrewLChangMD@gmail.com Disclosure Proton Center Development Corporation Scripps San Diego Proton Therapy Center
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer. Version NCCN.org. NCCN Guidelines for Patients.
NCCN Table of Contents Staging, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) NCCN Guidelines for Patients Version 1.2012 NCCN.org TM available at www.nccn.com Continue Version 1.2012,
More informationBreast Cancer Diagnosis, Treatment and Follow-up
Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce
More informationCertified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018)
Certified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018) I. Coordination of Care - 26% A. Breast health, screening, early detection, risk assessment and reduction 1. Issues related to
More informationDescriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma
S5.01 The tumour stage and stage grouping must be recorded to the extent possible, based on the AJCC Cancer Staging Manual (7 th Edition). 11 (See Tables S5.01a and S5.01b below.) Table S5.01a AJCC breast
More informationEducational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery
Educational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery Goal The goal of the Breast Surgery rotation is to develop the knowledge, skills and attitudes necessary to evaluate,
More informationBreast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationWhat is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine
What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Layman s terms: cancer starts when cells grow out of control (in any place in the body) and crowd out normal cells
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer. Version NCCN.org. NCCN Guidelines for Patients.
NCCN NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) NCCN Guidelines for Patients Version 3.2012 NCCN.org TM available at www.nccn.com Continue Version 3.2012, 09/10/12 National Comprehensive
More informationCase Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
More informationBREAST SURGERY PROGRESS TEST Name:
General Surgery Residency Program Excellent surgeons BREAST SURGERY PROGRESS TEST Name: Choose the BEST answer for the following questions. 1. All of the following factors are associated with an increased
More informationBreast Cancer: Noninvasive and Special Situations
1182 NCCN Breast Cancer: Noninvasive and Special Situations Clinical Practice Guidelines in Oncology Robert W. Carlson, MD; D. Craig Allred, MD; Benjamin O. Anderson, MD; Harold J. Burstein, MD, PhD; W.
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast
Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationNCCN Clinical Practice Guidelines in Oncology. Breast Cancer V Continue.
Clinical in Oncology V.2.2007 Continue www.nccn.org Panel Members * Robert W. Carlson, MD/Chair Stanford Hospital and Clinics * Benjamin O. Anderson, MD Fred Hutchinson Cancer Research Center/Seattle Cancer
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationCancer Endorsement Maintenance 2011-Maintenance Measures
Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212
More informationBreast Cancer Update 2018 The Latest in Diagnosis and Treatment SARATH K, PALAKODETI, DO, FAACS GENERAL, BREAST, AND COSMETIC SURGEON TOLEDO CLINIC
Breast Cancer Update 2018 The Latest in Diagnosis and Treatment SARATH K, PALAKODETI, DO, FAACS GENERAL, BREAST, AND COSMETIC SURGEON TOLEDO CLINIC Objectives Identify breast lesions and masses, and know
More informationPatient Guide to Breast Cancer Surgery and Treatment. Mercy Cancer Services. baggotstreet.mercy.net/benefits. Your life is our life s work.
Patient Guide to Breast Cancer Surgery and Treatment Your life is our life s work. baggotstreet.mercy.net/benefits Mercy Cancer Services Introduction An estimated one out of eight women will develop breast
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer. Version NCCN.org. Continue
NCCN NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Version 1.2014 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue Version 1.2014, 12/18/13 National Comprehensive
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer. Version NCCN.org. Continue
NCCN NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Version 1.2013 NCCN.org NCCN Guidelines for Patients available at www.nccn.com Continue Version 1.2013, 02/01/13 National Comprehensive
More informationPathology Report Patient Companion Guide
Pathology Report Patient Companion Guide Breast Cancer - Understanding Your Pathology Report Pathology Reports can be overwhelming. They contain scientific terms that are unfamiliar and might be a bit
More informationLesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node
Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node Oil Cyst Mass, Intermediate Concern Microlobulated Margins Obscured Margins Mass, Favoring Malignant Indistinct
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationB REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment
B REAST STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi c a b c d TUMOR SIZE:
More informationARROCase - April 2017
ARROCase - April 2017 Radiation Indications in the setting of Neoadjuvant chemotherapy for Breast Cancer Lauren Colbert, MD, MSCR Faculty Mentor: Benjamin Smith, MD UT MD Anderson Cancer Center 37 year
More informationClassification System
Classification System A graduate of the Breast Oncology training program should be able to care for all aspects of disease and/or provide comprehensive management. When referring to a discipline of training
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer. Version NCCN.org. Continue
NCCN NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Version 3.2014 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue Version 3.2014, 04/01/14 National Comprehensive
More informationB REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment
B REAST STAGING FORM Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi a b c a b c d TUMOR SIZE: S TAGE
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationBreast. Presentation Outline
Breast FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.02 Presentation Outline Overview Anatomy of Breast Multiple Primary
More informationBreast. FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.
Breast FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.02 Presentation Outline Overview Anatomy of Breast Multiple Primary
More informationInes Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
More informationDepartment of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Department of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India Evidence-Based Pragmatic SGPGI Breast Cancer Management Protocols (Summary) Background:
More informationPresented by: Lillian Erdahl, MD
Presented by: Lillian Erdahl, MD Learning Objectives What is Breast Cancer Types of Breast Cancer Risk Factors Warning Signs Diagnosis Treatment Options Prognosis What is Breast Cancer? A disease that
More information乳癌化療指引. Breast Cancer
乳癌化療指引 103 年 12 月第五版 99-102 年, 第一至四版 注意事項 : 本院癌症團隊基於實證醫學制定此化學治療指引 : 本院癌症團隊基於實證醫學制定此化學治療指引, 實證醫學之結論源自臨床詴驗, 實證醫學之結論源自臨床詴驗, 惟參與臨床詴驗之研究對象多以 70 歲以下之病人為主, 故建議 70 歲以上病人接受治療時, 應依據病人實際臨床狀況進行抗癌藥物劑量之調整! 健保藥品給付限制註記說明
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationBreast Cancer FAQ. How does Breast Cancer spread? Breast cancer spreads by invading into
FAQ Breast Cancer What is Breast Cancer? Breast Cancer is the second leading cause of cancer deaths in women today (second to lung cancer) and is the most common cancer among women excluding non-melanoma
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer. Version NCCN.org. Continue
NCCN NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Version 3.2013 NCCN.org NCCN Guidelines for Patients available at www.nccn.com Continue Version 3.2013, 05/03/13 National Comprehensive
More informationNCCN Clinical Practice Guidelines in Oncology. Breast Cancer V Continue.
Clinical in Oncology V.1.2009 Continue www.nccn.org These guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking
More informationBreast Surgery: Yesterday, Today and Tomorrow
Breast Surgery: Yesterday, Today and Tomorrow Baptist Hospital Gladys L. Giron, MD, FACS October 11,2014 Homestead Hospital Baptist Children s Hospital Doctors Hospital Baptist Cardiac & Vascular Institute
More informationMultidisciplinary management of breast cancer
Multidisciplinary management of breast cancer C. Polgár 1,2 1 National Institute of Oncology 2 Semmelweis University Department of Oncology Incidence of breast cancer in Hungary 2014 Female population
More informationGeneral Information Key Points
The content of this booklet was adapted from content originally published by the National Cancer Institute. Male Breast Cancer Treatment (PDQ ) Patient Version. Updated September 29,2017. https://www.cancer.gov/types/breast/patient/male-breast-treatment-pdq
More informationPage 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit.
AHN-JHU Breast Cancer Symposium Novel Local Regional Clinical Trials March 22, 2019 Thomas B. Julian, MD, FACS Associate Medical Director, Cancer Program Development, ANH Cancer Institute Background In
More informationCase 1. BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care
BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care Leah Karliner, MD MAS University of California San Francisco Primary Care Medicine Update 2009 April 2009 Case 1 AR, a 60 year old African
More informationCase study 1. Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research
NCCN/JCCNB Seminar in Japan April 15, 2012 Case study 1 Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research Present illness: A 50y.o.premenopausal
More informationMy Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
More informationBreast Cancer TREATMENT APPROACHES STAGING TUMOUR BIOLOGY. Breast Cancer
45 Dr K Tabane MBChB,FCP(SA); Certificate of Medical Oncology (Physicians) Specialist Physician, Medical Oncologist, Director: Sandton Oncology According to the CANSA statistics, breast cancer is the most
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationBreast Cancer Pathway Map
Care Ontario Pathway Map 03.18 Printer Friendly Version Note: print 11x17 landscape for best results, some features and content are only available on web version of pathway map Prevention Screening Diagnosis
More informationWhen do you need PET/CT or MRI in early breast cancer?
When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial
More informationCase Scenario 1: Breast
Case Scenario 1: Breast A 63 year old white female presents with a large mass in her left breast. 4/15/13 Mammogram/US: 1. Left breast mammographic and sonographic at 3:00 measuring 7.1 cm highly suggestive
More informationExcerpts from the American College of Surgeons Educational Courses about Breast Disease:
1 Excerpts from the American College of Surgeons Educational Courses about Breast Disease: Gynecomastia Gynecomastia is a benign enlargement of the male breast that can be unilateral or bilateral. It typically
More informationBREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
More informationBreast health and screening
Breast health and screening Dr Kathy Wong MBBS (HK), FRCR (UK), FHKCR FHKAM (Radiology) Clinical Radiologist Department of Diagnostic and Interventional Radiology Kwong Wah Hospital Questions regarding
More informationBreast Cancer Screening and Treatment Mrs Belinda Scott Breast Surgeon Breast Associates Auckland
Breast Cancer Screening and Treatment 2009 Mrs Belinda Scott Breast Surgeon Breast Associates Auckland BREAST CANCER THE PROBLEM 1.1 million women per year 410,000 deaths each year Increasing incidence
More informationBreast Cancer: Current Approaches to Diagnosis and Treatment
Breast Cancer: Current Approaches to Diagnosis and Treatment Barbara L. Smith, MD, Ph.D. Massachusetts General Hospital Division of Surgical Oncology No Disclosures Incidence of Breast Cancer USA 2018
More informationBREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
More informationConservative Surgery and Radiation Stage I and II Breast Cancer
Conservative Surgery and Radiation Stage I and II Breast Cancer Variant 1: Premenopausal 41-year-old woman, 1.1-cm GII IDC, upper outer quadrant (UOQ), ER/PR ( ), HER2 ( ), primary excised with lumpectomy,
More informationMedical Treatment of Early Breast Cancer
J KMA Pharmacotherapeutics Medical Treatment of Early Breast Cancer Soon beom Kang, MD Department of Obstetrics & Gynecology, Seoul National University College of Medicine E mail : ksboo308@plaza.snu.ac.kr
More informationSheri Saluga A/P 2 May 1, Breast Cancer
Sheri Saluga A/P 2 May 1, 2010 Breast Cancer Cancer, one word common to the word and one word no one wants to hear. There are many forms of cancer but of particular interest is stomach cancer. So what
More informationMalignant Breast disorders
Malignant Breast disorders RISK FACTORS FOR BREAST CANCER Family Hx.: first- and second-degree relatives with breast cancer and their age at diagnosis. RISK FACTORS FOR BREAST CANCER (cont.) Hormonal Risk
More information乳癌化療指引. 104 年 12 月第六版 年,1 st - 5 th 版
乳癌化療指引 104 年 12 月第六版 99-103 年,1 st - 5 th 版 注意事項 : 本院癌症團隊基於實證醫學制定此化學治療指引 : 本院癌症團隊基於實證醫學制定此化學治療指引, 實證醫學之結論源自臨床試驗, 實證醫學之結論源自臨床試驗, 惟參與臨床試驗之研究對象多以 70 歲以下之病人為主, 故建議 70 歲以上病人接受治療時, 應依據病人實際臨床狀況進行抗癌藥物劑量之調整! 健保藥品給付限制註記說明
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationQuiz. b. 4 High grade c. 9 Unknown
Quiz 1. 10/11/12 CT scan abdomen/pelvis: Metastatic liver disease with probable primary colon malignancy. 10/17/12 Colonoscopy with polypectomy: Adenocarcinoma of sigmoid colon measuring at least 6 mm
More informationMaria João Cardoso, MD, PhD
Locally Advanced Breast Cancer Specific Issues in LocorregionalTreatment Surgery, MD, PhD Head Breast Surgeon Breast Unit, Champalimaud Foundation Lisbon, Portugal 1 Conflict of Interest Disclosure No
More informationBreast cancer staging update. Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director
Breast cancer staging update Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director 1 1 Review of the AJCC 8 th edition breast cancer staging Review of genomic assays as stage modifiers
More informationBREAST SURGERY - SYLLABUS 2014
UNION EUROPÉENNE DES MÉDECINS SPÉCIALISTES Association internationale sans but lucratif International non-profit organisation AVENUE DE LA COURONNE, 20 T +32 2 649 51 64 BREAST SURGERY - SYLLABUS 2014
More informationSeventh Edition Staging 2017 Breast
Seventh Edition Staging 2017 Breast Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express written
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationWelcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar
American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director Welcome to American College of Surgeons Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar Moderator:
More informationAJCC CANCER STAGE. Site-Specific Instructions - BREAST. Reference: AJCC Cancer Staging Manual, 7 th Edition
Slide 1 AJCC CANCER STAGE Site-Specific Instructions - BREAST Reference: AJCC Cancer Staging Manual, 7 th Edition In this presentation, we are going to review the AJCC Cancer Staging criteria for the breast
More informationBreast Cancer: Selected Topics for the Primary Care Clinician
Breast Cancer: Selected Topics for the Primary Care Clinician Leah Karliner, MD MAS October 2009 Primary Care Medicine: Principles and Practice OUTLINE Incidence and Mortality Risk Factors and Risk Reduction/Prevention
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationTypes of Breast Cancer
IOWA RADIOLOGY 1 Types of Breast Cancer 515-226-9810 Ankeny Clive Downtown Des Moines IOWA RADIOLOGY 1 Table of Contents Introduction... 1 Ductal Carcinoma... 2 Paget s Disease of the Nipple... 8 Lobular
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
More information2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights
2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights Mylin A. Torres, M.D. Director, Glenn Family Breast Center Associate Professor Department of Radiation Oncology Winship Cancer Institute
More informationPET/CT in breast cancer staging
PET/CT in breast cancer staging Anni Morsing Consultant, PhD, DMSc Rigshospitalet 1 18F- FDG PET/CT for breastcancer staging Where is the clinical impact? To which women should 18F- FDG PET/CT be offered?
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Breast Cancer. Pathologic Staging Updates Breast Cancer
Pathologic Staging Updates in Breast Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationROLE OF MRI IN SCREENING, DIAGNOSIS AND MANAGEMENT OF BREAST CANCER. B.Zandi Professor of Radiology
ROLE OF MRI IN SCREENING, DIAGNOSIS AND MANAGEMENT OF BREAST CANCER B.Zandi Professor of Radiology Introduction In the USA, Breast Cancer is : The Most Common Non-Skin Cancer The Second Leading cause of
More informationTake Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules Case 1 72 year old white female presents with a nodular thyroid. This was biopsied in
More informationFeasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study
[ABS-0078] GBCC 2018 Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study Eun Young Kim 1, Kwan Ho Lee 1, Yong
More information本院臨床指引乃根據 NCCN guideline 2015 V1 及 Japanese Gastric Cancer Association Guideline 2010 V3, 經多學科團隊論會共同修訂完成
前言 本院臨床指引乃根據 NCCN guideline 2015 V1 及 Japanese Cancer Association Guideline 2010 V3, 經多學科團隊論會共同修訂完成 制定人員 : 腫瘤內科 : 林育靖醫師 鄧仲仁醫師一般外科 : 吳建明醫師腸胃內科 : 梁程超醫師 林政寬醫師放射腫瘤 : 謝忱希醫師 徐晨雄醫師組織病理 : 黃文志醫師影像醫學 : 謝詔裕醫師核子醫學
More information